X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1321) 1321
Newsletter (292) 292
Publication (147) 147
Book Review (12) 12
Magazine Article (10) 10
Newspaper Article (9) 9
Book Chapter (6) 6
Dissertation (3) 3
Conference Proceeding (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ranolazine (1577) 1577
humans (620) 620
index medicus (598) 598
cardiac & cardiovascular systems (449) 449
animals (372) 372
male (322) 322
piperazines - therapeutic use (284) 284
female (257) 257
angina pectoris (234) 234
pharmacology & pharmacy (230) 230
research (220) 220
piperazines - pharmacology (210) 210
acetanilides - therapeutic use (202) 202
atrial fibrillation (189) 189
angina pectoris - drug therapy (175) 175
care and treatment (172) 172
treatment outcome (168) 168
analysis (166) 166
late sodium current (166) 166
acetanilides - pharmacology (163) 163
ischemia (160) 160
drug therapy (151) 151
cardiovascular (145) 145
enzyme inhibitors - therapeutic use (139) 139
heart (139) 139
aged (137) 137
angina (135) 135
middle aged (135) 135
acetanilides (134) 134
electrocardiography (117) 117
antianginal agent (113) 113
arrhythmia (108) 108
sodium channel blockers - pharmacology (107) 107
heart failure (104) 104
arrhythmias (101) 101
cardiac patients (101) 101
piperazines - administration & dosage (101) 101
medical research (97) 97
cardiology (96) 96
reports (95) 95
rats (94) 94
medicine, experimental (92) 92
article (88) 88
cardiovascular agents - therapeutic use (88) 88
atrial fibrillation - drug therapy (86) 86
dose-response relationship, drug (85) 85
abridged index medicus (84) 84
myocytes, cardiac - drug effects (83) 83
action potentials - drug effects (81) 81
sodium channel blockers - therapeutic use (80) 80
anti-arrhythmia agents - pharmacology (79) 79
anti-arrhythmia drugs (79) 79
dosage and administration (77) 77
acetanilides - administration & dosage (76) 76
diabetes (76) 76
piperazines - adverse effects (75) 75
rabbits (75) 75
disease models, animal (74) 74
drugs (74) 74
exercise tolerance (74) 74
anti-arrhythmia agents - therapeutic use (73) 73
enzyme inhibitors - pharmacology (73) 73
ranolazine - therapeutic use (73) 73
myocardial ischemia - drug therapy (71) 71
chronic angina (69) 69
coronary heart disease (69) 69
randomized controlled-trial (69) 69
chronic disease (68) 68
sodium - metabolism (68) 68
amlodipine (66) 66
inhibition (66) 66
long-qt syndrome (66) 66
pharmacology (66) 66
risk factors (66) 66
chronic stable angina (65) 65
amiodarone (64) 64
myocytes, cardiac - metabolism (64) 64
time factors (64) 64
acetanilides - adverse effects (63) 63
coronary artery disease (63) 63
electrophysiology (63) 63
atrial-fibrillation (62) 62
double-blind method (61) 61
acute coronary syndromes (60) 60
physiology (60) 60
physiological aspects (59) 59
repolarization (59) 59
internal medicine (58) 58
peripheral vascular disease (58) 58
atrial fibrillation - physiopathology (57) 57
biological products industry (57) 57
drug therapy, combination (57) 57
medicine & public health (57) 57
myocardial ischemia (57) 57
clinical trials (56) 56
double-blind (55) 55
antiarrhythmic drugs (54) 54
cardiovascular disease (54) 54
heart rate - drug effects (54) 54
heart-failure (54) 54
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1565) 1565
German (24) 24
Spanish (16) 16
Italian (13) 13
Russian (5) 5
Chinese (4) 4
French (4) 4
Japanese (3) 3
Polish (3) 3
Czech (1) 1
Danish (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 01/2013, Volume 73, Issue 1, p. 55
Journal Article
Neuroscience Letters, ISSN 0304-3940, 08/2012, Volume 524, Issue 2, p. 101
a* Threshold tracking can non-invasively provide data on axonal membrane properties. a* Increased persistent Na.sup.+ current (Na.sub.p) is related to... 
Ranolazine
Journal Article
Heart Rhythm, ISSN 1547-5271, 11/2009, Volume 6, Issue 11, p. 1625
Ranolazine is an antianginal drug that inhibits the cardiac late Na.sup.+ current (I.sub.Na). The selectivity of ranolazine to block late I.sub.Na relative to... 
Ranolazine
Journal Article
Biophysical Journal, ISSN 0006-3495, 01/2015, Volume 108, Issue 2, pp. 195a - 196a
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2004, Volume 43, Issue 5, pp. A128 - A128
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 07/2019, Volume 234, Issue 7, pp. 11587 - 11601
Cardiac hypertrophy and heart failure are characterized by increased late sodium current and abnormal Ca handling. Ranolazine, a selective inhibitor of the... 
Heart failure | ranolazine | transient | hypertrophy
Journal Article
Neuroscience Letters, ISSN 0304-3940, 06/2012, Volume 518, Issue 1, p. 36
a* Threshold tracking can non-invasively provide axonal membrane properties. a* Persistent Na.sup.+ current (Na.sub.p) is related to neurodegeneration and... 
Cyanides | Ranolazine
Journal Article
Journal of Pharmaceutical Sciences and Research, 02/2017, Volume 9, Issue 2, pp. 145 - 149
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 07/2016, Volume 26, Issue 13, pp. 3202 - 3206
Journal Article
Journal Article
Heart Rhythm, ISSN 1547-5271, 2015, Volume 12, Issue 5, pp. 872 - 878
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2016, Volume 18, Issue 5, pp. 463 - 474
Aim To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or... 
clinical trial | antidiabetic drug | glycaemic control | type 2 diabetes | randomized trial | Type 2 diabetes | Clinical trial | Randomized trial | Antidiabetic drug | Glycaemic control | Ranolazine - adverse effects | Ranolazine - pharmacokinetics | Metformin - therapeutic use | Ranolazine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Metformin - adverse effects | Hypoglycemia - prevention & control | Glycated Hemoglobin A - antagonists & inhibitors | Hypoglycemic Agents - blood | Drug Therapy, Combination - adverse effects | Drug Interactions | Sodium Channel Blockers - adverse effects | Sodium Channel Blockers - therapeutic use | Female | Sulfonylurea Compounds - blood | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Drug Resistance | Metformin - blood | Hypoglycemic Agents - therapeutic use | Sodium Channel Blockers - blood | Hyperglycemia - prevention & control | Ranolazine - blood | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Metformin - pharmacokinetics | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Aged | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Sodium Channel Blockers - pharmacokinetics | Hypoglycemic Agents - adverse effects | Glycosylated hemoglobin | Glimepiride | Care and treatment | Diabetes therapy | Confidence intervals | Diabetes | Clinical trials | Hemoglobin | Metformin | Diabetes mellitus
Journal Article